P353 MMX® a mesalazine and long-term safety: A pooled analysis

the need for and timing of infliximab dose escalation in two cohorts of patients with CD or UC. Methods: In this single-center study, dose intensification was determined by two senior staff specialized in IBD. We compared the rates of patients and of patients-months on infliximab who needed infliximab dose intensification (either by increasing the dose to 10mg/kg or by shortening the dosing interval) in the cohorts of CD or UC patients. We also compared the interval between infliximab first induction dose and the first escalated infliximab dose. Intensification-free survival was estimated by the Kaplan Meier method. Results: We evaluated 61 patients with CD (mean age 42 years; 54% female) and 41 patients with UC (mean age 44 years; 41% female). Three in four CD patients vs 83% UC patients (p = 0.38) were receiving an immunomodulator when infliximab is initiated. After a median follow-up of 12.5 months (IQR, 7 23 months) and 8.5 months (IQR, 5 13 months) for CD or UC patients, respectively, 16/61 (26%) of CD patients required infliximab intesification vs 16/41 (39%) of UC patients (p = 0.16). The likelihood of needing infliximab intensification per patient-month on infliximab was 1.5% vs 3.9% (p < 0.001) for CD and UC, respectively. In patients who underwent infliximab optimization, median time between the first infliximab induction dose and the first escalated dose was 10.5 (IQR, 8.7 15.2) months vs 6.2 (IQR, 3.5 8.3) months (p = 0.02) for CD and UC, respectively. Survival curves showed that patients with UC had an increased probability of needing infliximab dose intensification when compared with CD patients. Conclusions: The likelihood of needing infliximab dose intensification is higher in UC patients when compared with CD patients. Patients with UC required intensification of infliximab dosing earlier and infliximab intensification-free survival was also lower in these patients.